Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


WHO Working On ‘Evolved’ Model For COVID-19 Licensing Platform

Executive Summary

With companies still reluctant to share their IP and knowledge via the C-TAP platform, stakeholders will be offered the chance to comment on a proposed new model that is expected to cover drugs for other high-priority diseases.

You may also be interested in...

Coronavirus Notebook: EMA OKs Updated Cominarty Vaccine, UK Brings Forward Vaccination Campaign Amid Spread Of BA.2.86 Strain

The World Health Organization’s C-TAP has signed new COVID-19 vaccine licensing deals with Medigen Vaccine Biologics of Taiwan and a Spanish research body, while the WHO and UNICEF say overall immunization rates are rebounding after the pandemic backslide, but not in all countries equally.

EU Critical Medicines List To Be Ready ‘Within Days’

Members of the European Parliament were told that once the list was out, work would begin on identifying the products most vulnerable to supply chain problems.

Controversial EU Study On Pharma Innovation & Access Sees The Light Of Day

Members of the European Parliament committee charged with leading the negotiations on the review of the EU pharmaceutical legislation have been presented with a study backing cuts in data protection and wider joint procurement of medicines outside emergency situations.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts